Hims & Hers Weight LossvsMochi Health Compounded GLP-1

Semaglutide is a GLP-1 receptor agonist — it mimics glucagon-like peptide-1, a gut hormone released after eating. It slows stomach emptying, signals fullness to the brain's appetite centers, and reduces hunger and food "noise," so people tend to eat less. It also stimulates insulin secretion and helps with blood-sugar control. "Compounded" semaglutide is the same molecule custom-mixed by a pharmacy rather than mass-manufactured and FDA-approved like Wegovy or Ozempic. Hims sold it (typically as a self-injected liquid drawn from a multi-dose vial, and later an oral form) under the temporary legal allowance that existed only while branded semaglutide was officially in shortage.

You take a weekly subcutaneous injection of compounded semaglutide (a GLP-1 receptor agonist) or compounded tirzepatide (a dual GIP/GLP-1 agonist). These hormones slow how fast your stomach empties and signal fullness to the brain, so you eat less without feeling deprived. A Mochi clinician sets your starting dose and titrates it upward over weeks to balance results against side effects.

The efficacy data comes from branded semaglutide, since compounded copies are not separately tested in clinical trials. In the pivotal STEP 1 trial (Wilding et al., NEJM 2021; 1,961 adults), once-weekly injectable semaglutide 2.4 mg produced a mean weight loss of 14.9% at 68 weeks versus 2.4% with placebo, and 86.4% of treated participants lost at least 5% of body weight. The newer oral semaglutide 25 mg (OASIS 4 trial, 64 weeks) showed a mean loss of about 13.6% when counting all randomized participants regardless of whether they stopped treatment, and roughly 16.6% among those who stayed on the drug, versus about 2.4-2.7% with placebo. Compounded products that genuinely contain correctly dosed, properly sourced semaglutide would be expected to perform comparably because it is the same molecule — but their purity, potency, and consistency are not FDA-verified, so individual results and safety can vary.

Mochi uses the same active molecules studied in landmark trials. In STEP 1, branded semaglutide 2.4 mg produced about 14.9% average body-weight loss over 68 weeks; in SURMOUNT-1, branded tirzepatide 15 mg produced about 20.9% over 72 weeks. Compounded formulations are not separately FDA-tested, so trial results for branded drugs are a reference point, not a guarantee. Individual results vary.

The most common side effects are gastrointestinal: nausea, diarrhea, vomiting, constipation, and abdominal pain — usually mild-to-moderate, worst when the dose increases, and often easing over time. Less common but serious risks include pancreatitis, gallstones, kidney injury from dehydration, low blood sugar (especially when combined with diabetes medicines), and a boxed warning for thyroid C-cell tumors based on rodent studies. A distinct risk specific to compounded multi-dose vials: the FDA has logged adverse-event reports — more than 500 for compounded semaglutide as of 2025 — tied largely to self-dosing errors, including cases where patients drew 5 to 20 times the intended dose by confusing milligrams, milliliters, and "units," with some events requiring hospitalization. Always confirm the exact dose and units with your prescriber before injecting, and seek medical care if you suspect an overdose.

Most side effects are gastrointestinal (nausea, diarrhea, constipation, vomiting) and tend to ease as your body adjusts and as the dose is titrated slowly. Rare but serious risks include pancreatitis and gallbladder disease. Because the product is compounded, dosing-error and quality risks exist; report unusual symptoms to your clinician promptly. This is educational information, not medical advice.

As of 2026, the compounded semaglutide that made Hims popular ran roughly $150-$250 per month, with promotional first-month or longer-plan offers sometimes advertised lower. With the program winding down, new Hims patients are generally directed to FDA-approved options: branded injectable Wegovy and the oral Wegovy pill have been advertised on the platform in roughly the $249-$299/month range and Zepbound somewhat higher (around $399/month), with some lower-cost subscription plans advertised from about $149/month. Crucially, these are cash/subscription prices; with commercial insurance plus a manufacturer savings card, branded Wegovy can drop to as little as $0-$25/month for eligible patients — often making an approved drug cheaper than people expect. Prices change frequently and vary by plan and eligibility; confirm current figures directly with Hims and check your insurance coverage.

Budget about $178/month for semaglutide ($79 membership + $99 medication) or $278/month for tirzepatide ($79 + $199), as of May 2026. A $39 first-month membership promo lowers the initial cost. Insurance does not cover compounded medication, but membership can drop to ~$69/mo with qualifying insurance on the Wellness Plus plan.

Branded semaglutide (Wegovy) is FDA-approved for adults with a BMI of 30 or higher, or 27 or higher with a weight-related condition such as high blood pressure, type 2 diabetes, or high cholesterol, used alongside a reduced-calorie diet and increased physical activity. Hims's telehealth model requires an online medical consultation. You should NOT use semaglutide if you or a family member has a history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), or if you've had a serious allergic reaction to it. It is not recommended during pregnancy, while breastfeeding, or when trying to conceive, and should be used cautiously with a history of pancreatitis, gallbladder disease, kidney problems, or severe gastrointestinal disease. Per FDA guidance, compounded versions specifically should be reserved for patients whose needs genuinely cannot be met by an FDA-approved product. Only a qualified clinician can determine whether semaglutide is appropriate for you.

Generally for US adults seeking medical weight management who clear a clinician's telehealth evaluation. Not appropriate for people with a personal or family history of medullary thyroid carcinoma or MEN 2, and not for use during pregnancy. State availability varies.